PER-015-03已完成1 期
CLINICAL TRIAL II OF IROFULVEN EVERY TWO WEEKS IN PATIENTS WITH IRRESECABLE HEPATOCELLULAR CARCINOMA
MGI PHARMA, INC.,0 个研究点目标入组 0 人开始时间: 2003年3月11日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •- The patient must sign the written informed consent approved by the institutional committee for scientific review (IRB).
- •- The patient must have a histological or cytological diagnosis of hepatocellular carcinoma that has been considered unresectable.
- •- The patient should not have more than one previous therapeutic intervention for the treatment of hepatocellular carcinoma including surgical techniques, ablative,
- •chemo-embolization, and systemic chemotherapy.
排除标准
- •- Previous treatment with gene therapy.
- •- Women who are pregnant or breast-feeding.
- •- Patients with any concomitant systemic disorder (in the opinion of the researcher)
- •- Patients who have completed or who have been withdrawn from this study or any other study with irofulven.
研究者
相似试验
已完成
不适用
Study of Irofulven Plus Capecitabine in Patients With Advanced Thyroid CancerPER-086-04MGI PHARMA, INC.,
已完成
2 期
Phase II study of Eribulin every other week maintenance therapy, after induction therapy of Eribulin on day1 and 8 for 3 cycles, in patients with hormone receptor positive and HER2-negative advanced recurrent breast cancer.JPRN-UMIN000013928onprofit Organization Japan Clinical Cancer Research Organization60
已完成
2 期
Study of Irofulven Plus Capecitabine in Patients With Advanced Thyroid CancerThyroid CancerNCT00124527Eisai Inc.35
已完成
2 期
A Randomized Phase II/III Trial of Tri-weekly Intravenous versus Tri-weekly Intraperitoneal Carboplatin Both in Combination with Weekly Intravenous Paclitaxel for Newly Diagnosed Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal CancerEpithelial Ovarian, Fallopian Tube, and Primary Peritoneal CancerJPRN-UMIN000003670Gynecologic Oncology Trial and Investigation Consortium / Japanese Gynecologic Oncology Group655
已完成
不适用
CLINICAL PHASE II STUDY OF IROFULVEN IN COMBINATION WITH IRINOTECAN IN PATIENTS WITH ADVANCED SOLID TUMORS GASTROINTESTINALES-C26 Malignant neoplasm of other and ill-defined digestive organsMalignant neoplasm of other and ill-defined digestive organsC26PER-056-02MGI PHARMA, INC.,